ClinicalTrials.gg
CompletedNCT01592786Updated Aug 7, 2014Results posted

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

A Phase 2 interventional study of Memantine Hydrochloride (HCl) in Autism Spectrum Disorder (ASD), Autism and Autistic Disorder, sponsored by Forest Laboratories. Completed at 118 sites in 18 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2014-08-07.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
906
Allocation
Not applicable
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
7th of 658
906 · median 50
Started
2012
with 25 others
Phase 2
101 of 773
15 open now
Registered
89th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 7th largest by enrollment of the 658 interventional ones that give a count, is one of 26 that started in 2012, is one of 101 in phase 2, and was the 89th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized withdrawal study.

Read the detailed description

This 50-week multicenter and multinational clinical study is comprised of a 2-week screening period, a 6-week open-label dose-titration period followed by a variable duration maintenance period (up to 42 weeks).

Patients with at least 12 weeks of investigational product exposure who meet the protocol specified responder criterion at two consecutive visits separated by at least two weeks are eligible to transition to a randomized withdrawal study. A responder is defined as a patient who demonstrates at least a 10 point improvement (reduction in score) in the Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 total raw score.

Weight based dose limits were selected in this study to ensure that exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng·h/mL which represents a 10-fold lower exposure than observed at the No observed adverse effect level (NOAEL) of 15 mg/kg/day in juvenile rats.

The weight-based dose limits in this study were as follows:

  • Group A: ≥ 60 kg; maximum 15 mg/day
  • Group B: 40-59 kg; maximum 9 mg/day
  • Group C: 20-39 kg; maximum 6 mg/day
  • Group D: \< 20 kg; maximum 3 mg/day
03

Conditions studied

  • Autism Spectrum Disorder (ASD)
  • Autism
  • Autistic Disorder
  • Asperger's Disorder
  • Asperger's
  • Pediatric Autism
  • Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Keywords

  • Autism Spectrum Disorder (ASD)
  • Autism
  • Autistic Disorder
  • Asperger's Disorder
  • Asperger's
  • Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
  • Memantine
  • Pediatric Disorder
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female outpatients.
  2. Age of 6-12.
  3. Meet , Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
  4. Have a family that is sufficiently organized and stable to guarantee adequate safety monitoring and continuous attendance to clinic visits for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Have enrolled in Study MEM-MD-57A
  2. Medical conditions that might interfere with the conduct of the study, confound interpretation of the study results, or endanger the patient's well-being.
  3. Participation in any other clinical investigation using an experimental drug within 30 days of screening.
  4. Having any primary psychiatric (Axis I) diagnosis other than autism, Asperger's Disorder, and PDD-NOS.
  5. Meeting criteria for bipolar I disorder, psychotic disorder not otherwise specified, posttraumatic stress disorder, schizophrenia, or major depressive disorder within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
906 participants (actual)

Study arms

  • Experimental
    Memantine Hydrochloride (HCl)

    Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.

    Drug: Memantine Hydrochloride (HCl)

Interventions

  • Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.

    Also known as: Namenda

06

What researchers measure

Primary outcomes

  1. Number of Confirmed Social Responsiveness Scale (SRS) Responders

    A confirmed SRS responder was defined as a patient who had at least 12 weeks of exposure to memantine, and a ≥ 10-point reduction in the SRS total raw score relative to baseline at 2 consecutive visits separated by at least 2 weeks. The SRS is a 65-item, caregiver-rated assessment scale that measures observable items on social behavior and social language use, as well as characteristics of autism in a naturalistic social setting. Each item is rated on a scale from 0 (never true) to 3 (almost always true). The SRS total raw score ranges from 0 to 195; a higher score indicates greater severity of social impairment.

    Time frame: Visit 1 (Baseline) to Visit 8 (week 48/Final Visit)

07

Results

Posted Aug 7, 2014

Participant flow

Patient recruitment occurred over an eleven month period, from June of 2012 to May of 2013, at 118 study sites, located in the United States and 17 other countries.

Participant flow — Overall Study
MilestoneMemantine Hydrochloride (HCl)
Started903
Completed765
Not completed138
Withdrew: Adverse event60
Withdrew: Lack of efficacy19
Withdrew: Protocol violation14
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up19
Withdrew: Other3

Outcome measures

PrimaryNumber of Confirmed Social Responsiveness Scale (SRS) Responders

A confirmed SRS responder was defined as a patient who had at least 12 weeks of exposure to memantine, and a ≥ 10-point reduction in the SRS total raw score relative to baseline at 2 consecutive visits separated by at least 2 weeks. The SRS is a 65-item, caregiver-rated assessment scale that measures observable items on social behavior and social language use, as well as characteristics of autism in a naturalistic social setting. Each item is rated on a scale from 0 (never true) to 3 (almost always true). The SRS total raw score ranges from 0 to 195; a higher score indicates greater severity of social impairment.

Time frame:
Visit 1 (Baseline) to Visit 8 (week 48/Final Visit)
Reported as:
Number · participants
Number of Confirmed Social Responsiveness Scale (SRS) Responders
participantsMemantine Hydrochloride (HCl)
Responders517
Non responders351

Adverse events

Collected over Adverse event data was collected over a 14 month period from June 2012 to August 2013 at 118 study sites in the US and 17 other countries.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine Hydrochloride (HCl)—6/903 (0.7%)196/903 (21.7%)
Most frequent serious events
Most frequent serious events
EventMemantine Hydrochloride (HCl)
Abnormal behaviourPsychiatric disorders2/903
Accidental exposureInjury, poisoning and procedural complications1/903
ConstipationGastrointestinal disorders1/903
DisinhibitionPsychiatric disorders1/903
GastroenteritisGastrointestinal disorders1/903
Most frequent other events
Most frequent other events
EventMemantine Hydrochloride (HCl)
HeadacheNervous system disorders72/903
NasopharyngitisInfections and infestations57/903
PyrexiaGeneral disorders52/903
IrritabilityGeneral disorders49/903

Baseline characteristics

A total of 906 patients were enrolled in the open-label study. Of these, 903 patients received at least 1 dose of open-label treatment to comprise the Safety Population. 868 patients in the Safety Population also had at least 1 post-Visit 1 assessment of the SRS total raw score to comprise the Intent to Treat (ITT) population

Age, Continuous
Age, Continuous(Years)Memantine Hydrochloride (HCl)
Mean9.0 ± 1.9
Sex/Gender, Customized
Sex/Gender, Customized(participants)Memantine Hydrochloride (HCl)
Male759
Female144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Memantine Hydrochloride (HCl)
White768
Black or African American54
Asian54
American Indian or Alaska Native2
Native Hawaiian or Other Pacific Islander3
Other22
Hispanic or Latino102
Not Hispanic or Latino801
Region of Enrollment
Region of Enrollment(participants)Memantine Hydrochloride (HCl)
United States712
Australia0
Belgium11
Canada1
Colombia8
Estonia6
France14
Hungary20
Iceland5
Italy6
Korea, Republic of25
New Zealand2
Poland37
Serbia21
Singapore0
South Africa2
Spain17
Ukraine16
08

Study locations

118 sites
  • Forest Investigative Site 068
    Dothan, Alabama 36303, United States
  • Forest Investigative Site 005
    Phoenix, Arizona 85006, United States
  • Forest Investigative Site 055
    Tucson, Arizona 85718, United States
  • Forest Investigative Site 077
    Little Rock, Arkansas 72202-3591, United States
  • Forest Investigative Site 054
    Glendale, California 91206, United States
  • Forest Investigative Site 109
    Imperial, California 92251, United States
  • Forest Investigative Site 066
    Irvine, California 92612, United States
  • Forest Investigative Site 096
    Los Angeles, California 90024, United States
  • Forest Investigative Site 021
    San Francisco, California 94143-0984, United States
  • Forest Investigative Site 026
    Santa Ana, California 92701, United States
  • Forest Investigative Site 002
    Stanford, California 94305-5719, United States
  • Forest Investigative Site 078
    Boulder, Colorado 80304, United States
  • Forest Investigative Site 073
    Centennial, Colorado 80112, United States
  • Forest Investigative Site 052
    Washington, District of Columbia 20010-2970, United States
  • Forest Investigative Site 075
    Bradenton, Florida 32751, United States
  • Forest Investigative Site 080
    Gainesville, Florida 32607, United States
  • Forest Investigative Site 117
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 065
    Maitland, Florida 32751, United States
  • Forest Investigative Site 118
    Miami, Florida 33155, United States
  • Forest Investigative Site 085
    Oakland Park, Florida 33334, United States
  • Forest Investigative Site 115
    Orange City, Florida 32763, United States
  • Forest Investigative Site 124
    Orlando, Florida 32803, United States
  • Forest Investigative Site 125
    Orlando, Florida 32803, United States
  • Forest Investigative Site 062
    Orlando, Florida 32806, United States
  • Forest Investigative Site 114
    Orlando, Florida 32839, United States
  • Forest Investigative Site 067
    Tampa, Florida 33612, United States
  • Forest Investigative Site 101
    Wellington, Florida 33414, United States
  • Forest Investigative Site 102
    Libertyville, Illinois 60048, United States
  • Forest Investigative Site 023
    Naperville, Illinois 60563, United States
  • Forest Investigative Site 082
    Evansville, Indiana 47713, United States
  • Forest Investigative Site 123
    Fort Wayne, Indiana 46805, United States
  • Forest Investigative Site 056
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 084
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 106
    Wichita, Kansas 67214-3199, United States
  • Forest Investigative Site 061
    Louisville, Kentucky 40202, United States
  • Forest Investigative Site 074
    Owensboro, Kentucky 42301, United States
  • Forest Investigative Site 095
    Lake Charles, Louisiana 70605, United States
  • Forest Investigative Site 091
    New Orleans, Louisiana 70112, United States
  • Forest Investigative Site 086
    Rockville, Maryland 20852, United States
  • Forest Investigative Site 059
    Newton, Massachusetts 02459, United States
  • Forest Investigative Site 108
    Springfield, Massachusetts 01199, United States
  • Forest Investigative Site 116
    Lincoln, Nebraska 68516, United States
  • Forest Investigative Site 097
    Lincoln, Nebraska 68526, United States
  • Forest Investigative Site 130
    Henderson, Nevada 89052, United States
  • Forest Investigative Site 104
    Las Vegas, Nevada 89128, United States
  • Forest Investigative Site 136
    Neptune, New Jersey 07753, United States
  • Forest Investigative Site 127
    Toms River, New Jersey 08755, United States
  • Forest Investigative Site 081
    Albuquerque, New Mexico 87108-5129, United States
  • Forest Investigative Site 107
    Albuquerque, New Mexico 87109, United States
  • Forest Investigative Site 098
    Bronx, New York 10467, United States
  • Forest Investigative Site 072
    Chapel Hill, North Carolina 27514, United States
  • Forest Investigative Site 069
    Avon Lake, Ohio 44012, United States
  • Forest Investigative Site 001
    Columbus, Ohio 43210, United States
  • Forest Investigative Site 019
    Oklahoma City, Oklahoma 73116, United States
  • Forest Investigative Site 092
    Tulsa, Oklahoma 74104, United States
  • Forest Investigative Site 053
    Gresham, Oregon 97030, United States
  • Forest Investigative Site 132
    Johnstown, Pennsylvania 15904, United States
  • Forest Investigative Site 131
    McMurray, Pennsylvania 15317, United States
  • Forest Investigative Site 100
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site 105
    Charleston, South Carolina 29407, United States
  • Forest Investigative Site 090
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 057
    Nashville, Tennessee 37232, United States
  • Forest Investigative Site 051
    Houston, Texas 77090, United States
  • Forest Investigative Site 070
    The Woodlands, Texas 77381, United States
  • Forest Investigative Site 028
    Clinton, Utah 84015, United States
  • Forest Investigative Site 141
    Ogden, Utah 84405, United States
  • Forest Investigative Site 029
    Salt Lake City, Utah 84106, United States
  • Forest Investigative Site 064
    Charlottesville, Virginia 22903, United States
  • Forest Investigative Site 113
    Norfolk, Virginia 23507, United States
  • Forest Investigative Site 071
    Bothell, Washington 98011, United States
  • Forest Investigative Site 119
    Charleston, West Virginia 25304, United States
  • Forest Investigative Site 063
    Middleton, Wisconsin 53562, United States
  • Forest Investigative Site 177
    Camperdown, New South Wales 2050, Australia
  • Forest Investigative Site 204
    Brussel, 1020, Belgium
  • Forest Investigative Site 203
    Bruxelles, 1090, Belgium
  • Forest Investigative Site 202
    Hoboken, 2660, Belgium
  • Forest Investigative Site 201
    Leuven, 3000, Belgium
  • Forest Investigative Site 155
    Toronto, Ontario M5B 1T8, Canada
  • Forest Investigative Site 227
    Barranquilla, Colombia
  • Forest Investigative Site 228
    Bello, Colombia
  • Forest Investigative Site 226
    Bogota, Colombia
  • Forest Investigative Site 276
    Tallinn, 10617, Estonia
  • Forest Investigative Site 329
    Bron, Rhone 69500, France
  • Forest Investigative Site 326
    Paris, 75935, France
  • Forest Investigative Site 379
    Budapest, 1021, Hungary
  • Forest Investigative Site 381
    Budapest, 1026, Hungary
  • Forest Investigative Site 376
    Budapest, 1083, Hungary
  • Forest Investigative Site 378
    Budapest, 1089, Hungary
  • Forest Investigative Site 382
    Gyula, 5700, Hungary
  • Forest Investigative Site 380
    Szeged, 6725, Hungary
  • Forest Investigative Site 401
    Kopavogur, 200, Iceland
  • Forest Investigative Site 453
    Roma, 165, Italy
  • Forest Investigative Site 452
    Siena, 53100, Italy
  • Forest Investigative Site 704
    Yangsan-si, Gyeongsangnam-do 626-770, Korea, Republic of
  • Forest Investigative Site 702
    Seoul, 110744, Korea, Republic of
  • Forest Investigative Site 703
    Seoul, 120-752, Korea, Republic of
  • Forest Investigative Site 701
    Seoul, 138-736, Korea, Republic of
  • Forest Investigative Site 526
    Wellington, 6012, New Zealand
  • Forest Investigative Site 579
    Gdansk, 80-542, Poland
  • Forest Investigative Site 578
    Gdansk, 80-952, Poland

Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 7, 2012
Start
Jun 2012
Primary completionActual
Jul 2013
CompletionActual
Aug 2013
Results first posted
Aug 7, 2014
Last update
Aug 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01592786
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Jun 2012
Primary completion
Jul 2013
Completion
Aug 2013
Results posted
Aug 7, 2014
Last update
Aug 7, 2014

Study contacts

Jordan Lateiner, MS, MBA
study director · Forest Research Institute, Inc.- A Subsidiary of Forest Laboratories, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion